Chosa Oncology opens Boston office to support US rollout of Platin-DRP

Chosa Oncology opened a US presence in Boston, Massachusetts to support commercialization of its Platin-DRP biomarker platform.
Move targets the US as a core commercial market, aiming to build partnerships across clinical collaborators, labs, drugmakers, investors.
Initial rollout plans to offer Platin-DRP as a Research Use Only test for researchers, pharmaceutical companies, clinical partners.
US base is expected to support market entry, business development, partnership talks, engagement with the US oncology ecosystem.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief on June 23, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.